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ABSTRACT
Expression of bacterial type II toxin-antitoxin (TA)
systems is regulated at the transcriptional level
through direct binding of the antitoxin to pseudo-
palindromic sequences on operator DNA. In this con-
text, the toxin functions as a co-repressor by stimu-
lating DNA binding through direct interaction with
the antitoxin. Here, we determine crystal structures
of the complete 90 kDa heterooctameric VapBC1
complex from Caulobacter crescentus CB15 both
in isolation and bound to its cognate DNA opera-
tor sequence at 1.6 and 2.7 A˚ resolution, respec-
tively. DNA binding is associated with a dramatic
architectural rearrangement of conserved TA inter-
actions in which C-terminal extended structures of
the antitoxin VapB1 swap positions to interlock the
complex in the DNA-bound state. We further show
that a pseudo-palindromic protein sequence in the
antitoxin is responsible for this interaction and re-
quired for binding and inactivation of the VapC1 toxin
dimer. Sequence analysis of 4127 orthologous VapB
sequences reveals that such palindromic protein se-
quences are widespread and unique to bacterial and
archaeal VapB antitoxins suggesting a general prin-
ciple governing regulation of VapBC TA systems. Fi-
nally, a structure of C-terminally truncated VapB1
bound to VapC1 reveals discrete states of the TA
interaction that suggest a structural basis for toxin
activation in vivo.
INTRODUCTION
Toxin-antitoxin (TA) systems play important roles formany
prokaryotic organisms in survival during stress, such as
starvation and antibiotic pressure (1). In most cases, toxin
activation causes a halt in growth leading to a dormant or
persistent state, which appears to be highly relevant for un-
derstanding bacterial pathogenesis and behaviour during
chronic and recurring infections (2,3). TA systems are found
ubiquitously among bacteria and archaea and are present
in surprisingly large numbers in some organisms (4,5). In
the most well-characterized and abundant class, the type II
TA systems, the toxin and antitoxin form a tight protein–
protein complex in which the activity of the toxin is in-
hibited during normal growth. When the cell experiences
stress, increased levels of the alarmone molecule (p)ppGpp
causes activation of specific proteases that destroy the an-
titoxin by proteolytic cleavage, subsequently releasing and
activating the toxin (6). At the genomic level, type II TA
genes are arranged in bicistronic operons with the antitoxin
preceding the toxin, ensuring rapid inhibition of the toxin
through translational coupling. Expression from TA loci is
further regulated at the transcriptional level through direct
binding of the antitoxin to pseudo-palindromic sequences
in the promoter region (Figure 1A) (7). During this pro-
cess, the toxin acts as a co-repressor by structurally stabi-
lizing and increasing the affinity of the antitoxin for DNA
(7,8). In an additional layer of regulatory complexity, some
TA systems display what is known as conditional coopera-
tivity, whereby the toxin causes de-repression at high con-
centrations by binding to additional sites on the antitoxin
and destabilizing the operator-DNA interaction (9–11).
In the most abundant type II TA family, Virulence as-
sociated proteins B and C (VapBC), the VapC toxin and
the VapB antitoxin form a large, heterooctameric VapB4C4
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complex in which the antitoxin inhibits the toxin by wrap-
ping its C-terminus around it (12–14). Available crystal
structures of VapBC complexes have revealed some of
the molecular diversity of the interaction and shown that
one VapB antitoxin can inhibit either one or two toxin
molecules simultaneously using a 1:1 proximal, 1:1 distal
or 1:2 mode of interaction (12–18). The N-terminus of
VapB dimerizes to form a DNA binding domain belong-
ing to either the AbrB, helix-turn-helix, ribbon-helix-helix
or PhD/YefM type, which is required for transcriptional
regulation (7). When activated, VapC toxins are functional
endo-ribonucleases belonging to the PIN domain family
(19,20) and appear to harbour RNase activity against spe-
cific cellular RNAs, including specific tRNA and rRNA
species (21–24). PIN domain proteins consist of a parallel
-sheet with -helices distributed on both sides that orga-
nize several conserved, acidic residues into an active site that
binds two Mg2+ ions and is mechanistically similar to T4
phage RNase H (19,20). Upon interaction with VapB, pos-
itively charged residues from the antitoxin are inserted into
the toxin active site, displacing the divalent metal ions thus
rendering the PIN domain inactive (12,25).
Although structures of VapBC complexes in a range of
states are available from several organisms, the conforma-
tional changes occurring upon DNA binding as well as the
molecular basis for toxin activation are still not understood.
To address this, we decided to determine crystal structures
of the intact VapBC1 complex from the Gram-negative,
oligotrophic bacterium Caulobacter crescentus CB15, both
in isolation and bound to cognate operator DNA. Both
on and off DNA, VapBC1 forms a compact heterooc-
tameric assembly with two protruding AbrB-type DNA-
binding domains. C-terminal extensions of two of the four
VapB1 antitoxins in the complex interact tightly with all
four VapC1 active sites in a 1:2 ratio. Upon binding DNA,
the complex expands to dock the two AbrB domains into
adjacent major grooves, causing a distortion of the regu-
lar B-form DNA double helix. Remarkably, the VapB1 C-
termini switch from cis to trans conformation in the DNA-
bound form, effectively interlocking the complex on DNA
through non-covalent cross-linking that may have impor-
tant consequences for cooperativity. Moreover, we show
that the structural switch and recognition of the 2-fold sym-
metric VapC1 dimers is achieved by a pseudo-palindromic
protein sequence in VapB1, which is a widespread feature
of both bacterial and archaeal VapB antitoxins. Finally, we
present a structure of VapC1 bound to a truncated version
ofVapB1 that only contains one half of the palindromicmo-
tif, which suggests a possiblemechanism for toxin activation
in vivo.
MATERIALS AND METHODS
Protein purification and oligomer analysis
The Caulobacter crescentus CB15 vapB1 and vapC1 genes
(locus tags CC0032 and CC0031) were amplified by PCR,
digested with EcoRI/BamHI or BamHI/HindIII, and lig-
ated together into EcoRI/HindIII-digested expression vec-
tor pMG25 generating pKW912HB, which was used for ex-
pressing seleno-methionine (Se-Met) substituted VapBC1
complex in E. coli B834 (DE3). Cells were initially grown
in minimal media supplemented 25 g/ml methionine at
25◦C until OD600 = 1, then pelleted and grown in minimal
media without methionine for an additional 6 h at 37◦C.
Upon methionine depletion, 50 g/ml Se-Met was added
to the cells, which were further incubated at 37◦C for 30 min
before protein expression was induced with 1 mM isopropyl
-D-1-thiogalactopyranoside and the cells grown overnight
at 25◦C under vigorous shaking. For purification, the cells
were lysed by sonication and the raw extract cleared by cen-
trifugation and purification on a 1 ml HisTrapTM column
(GE Healthcare) eluting in 50 mM Tris-HCl pH 8.0, 500
mM KCl, 150 mM imidazole, 5 mM MgCl2, 10% glycerol
and 5 mM -mercaptoethanol (BME). The eluted protein
was precipitated overnight in 66% saturated (NH4)2SO4,
followed by ion exchange chromatography on both 1 ml
Source 15Q and 1 ml MonoQ columns (GE Healthcare)
using 50 mM Tris-Cl pH 8.8, 5 mM MgCl2, 5 mM BME
and a gradient into 1 M KCl in both cases. Final separa-
tion was achieved on a 24 ml Superdex 75 10/300 GL col-
umn (GE Healthcare) equilibrated in 25 mM Tris-HCl pH
8, 500 mM NaCl, 5 mM MgCl2 and 5 mM BME. Peak
fractions were concentrated to ∼9 mg/ml prior to crystal-
lization. Se-Met substituted complex was used both for the
apo andDNA-bound structures. For expression of the trun-
cated VapB1C:VapC1 complex, pKW912HB was modi-
fied by PCR by insertion of a stop codon at position 73
of VapB1. Native protein was expressed in Escherichia coli
BL21 (DE3) growing at 37◦C in LB media until OD600 =
0.6, followed by overnight expression at 25◦C after induc-
tion with 1 mM isopropyl -D-1-thiogalactopyranoside.
The cells were lysed and protein purified as described above.
Oligomer analysis of protein complexes was performed us-
ing a 24 ml Superdex 200 10/300 HR (GE Healthcare) col-
umn equilibrated in 25 mM Tris-HCl pH 8, 500 mMNaCl,
5 mMMgCl2 and 5 mM BME.
DNA oligos and binding assays
Two complementary 27-bp DNA oligos derived from
the promoter region of the C. crescentus vapbc1 operon
were synthesized (Eurofins Genomics) as follows: Fw,
5′-GGAACGTATATACGCATATTGACGGAG-3′ and
Rv, 5′-CTCCGTCAATATGCGTATATACGTTCC-3′.
The Fw oligo was synthesized both with (Fw-label) and
without a 5′ fluorescein label for visualization. For gel
filtration and crystallography, the oligos were dissolved
in standard TE Buffer to 80 M each, mixed 1:1 and
heated to 96◦C for 2 min then cooled to 19◦C to a final
concentration of 40 M duplex. To generate the labeled
duplex DNA, equal volumes of Fw-label and Rv (both
at 200 M) were mixed, heated to 96◦C for 2 min and
cooled to 19◦C, resulting in 100 M final DNA duplex.
Binding analysis by gel filtration was performed by mixing
equal volumes of protein and DNA (both at 130 M), or
protein and DNA separately, and diluting 40x in binding
buffer (25 mM Tris-HCl, pH 8, 150 mM NaCl and 5 mM
MgCl2, 5 mM BME) before incubating at 37◦C for 1 h.
The samples were then loaded onto 24 ml Superdex200
10/300 GL column (GE Healthcare) pre-equilibrated in
binding buffer and monitored by A280 and A260 on an
A¨KTA system. For electrophoretic mobility shift assay
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(EMSA), samples containing a fixed concentration of
5′-fluorescein labelled DNA duplex (10 nM) and protein
complex concentrations varying from 6.25 nM to 1.6 M
were mixed in binding buffer (25 mM Tris-HCl, pH 8, 150
mMNaCl, 5 mMMgCl2, 5 mM BME) and incubated for 1
h at 37◦C, before separation on a 8% native polyacrylamide
gel electrophoresis gels and visualization by fluorescence
scanning at 495/517 nm (absorption/emission, Typhoon
Trio, GE Healthcare).
Crystallization and structure determination
Trigonal crystals of the isolated Se-Met VapBC1 complex
appeared in 3 M NaCl and 0.1 M Bis-Tris pH 5.5, whereas
plate-shaped crystals of VapB1C:VapC1 appeared in 0.1
M Na malonate pH 4.0 and 12% (w/v) PEG 3350. For
the DNA-bound structure, the Fw and Rv oligos were re-
suspended in TE buffer, mixed to 40 M duplex, heated
at 96◦C for 2 min and slowly cooled to 19◦C before co-
crystallization with the protein. DNA and protein were
mixed in a 4:1 molar ratio at 6 mg/ml protein, after which
plate-shaped crystals appeared in 20% (w/v) PEG 3350 and
0.2M succinic acid pH 7.0. All crystals were cryo-protected
in reservoir solution supplemented with 25% glycerol and
flash-frozen in liquid nitrogen prior to data collection.
Complete and highly redundant Se-Met single-wavelength
anomalous dispersion (SAD) data were collected at 0.972
A˚ for VapBC1 and VapBC1:DNA at the I911-3 beamline
at Max-lab (Lund, Sweden), while VapB1C:VapC1 native
datawere collected at the ID30B beamline at ESRF (Greno-
ble, France). All data sets were processed with XDS (26).
For VapBC1, 12 Se sites were located by Phenix.autosol
(27) and used for SAD phasing in PHASER. Phasing was
followed by automatic model building in Phenix.autobuild
(28), manual model building in Coot (29) and iterative
refinement with Phenix.refine (28). The final coordinates
were validated using MolProbity (28). The VapBC1:DNA
and VapB1C:VapC1 structures were determined by MR
using isolated VapBC1 as a search model. Both struc-
tures were manually rebuilt in Coot, iteratively refined with
Phenix.refine and validated with MolProbity.
Bioinformatics analysis
A manually curated database of VapBC pairs from a previ-
ous study (30) was used to determine typical size distribu-
tions for VapB and VapC proteins, respectively. To generate
a pool of potential vapBC loci for the analysis of VapB C-
terminal motifs, pairs of adjacently annotated open read-
ing frames matching the expected size distributions in the
correct order were then extracted from all publicly available
bacterial and archaeal genomes as of May 2016. For gene
pairs in which the second gene encoded a protein match-
ing to any of the PIN domain pfam models (PF01850,
PF08745, PF10130, PF13470, PF13638 or PF17146) (31),
the first gene was considered a valid vapB and included
in the analysis. To identify pseudo-palindromic protein se-
quence motifs in this pool, for each protein sequence s, we
identified all pairs of occurrences of arginine residues at po-
sitions i < j, where i > = 55 and j-i+1 was between 3 and
12, i.e. all sub-sequences s[i..j] = R. . .R of the protein se-
quence of lengths between 5 and 14, where the two argi-
nine residues were separated by between 3 and 12 residues.
Each such substring s[i..j] was then considered a ‘seed’
of a pseudo-palindromic motif (u, uRev), where u = s[i-
lbest]. . . s[i]. . . s[i+rbest] and uRev= s[j-rbest]s[j]. . . s[j+lbest], such
that distance Hamming-Blossum62 (u,uRev) is maximum,
i+rbest < j-rbest and lbest ≤ 4. The Hamming-Blossum62
(x[1..n], y[1..n]) distance between two strings x and y (of
equal length) is the sum of Blossum62 (x[i], y[i]) for i= 1,..,n
(32).
RESULTS
C. crescentus VapB1 inhibits two VapC1 toxins simultane-
ously
The Gram-negative, oligotrophic bacterium Caulobacter
crescentus CB15 contains a total of 14 type II TA loci, in-
cluding 4 relBE, 2 vapBC, 2 parDE, 2 hipBA, 1 hicBA, 1
higBA, in addition to two uncharacterized loci (4,5). To un-
derstand the structural basis for toxin and DNA binding
among distantly related VapBC orthologues, we decided to
perform an in-depth analysis of one of the two VapBC sys-
tems found in this organism identified by the genes CC 0031
(vapC1) and CC 0032 (vapB1). Based on both sequence
conservation and the ability of VapB1 to inhibit the toxi-
city of VapC1 (Supplementary Figure S1A), this locus rep-
resents a bona fide VapBC TA system (4,5). Se-Met substi-
tuted C. crescentus CB15 VapBC1 apo complex was gener-
ated by overexpression of the full-length operon in theMet-
auxotroph E. coli strain B834 (DE3) in minimal media, pu-
rified to homogeneity and crystallised, and the structure de-
termined to 1.6 A˚ using Se-Met SAD followed by automatic
structure building and iterative refinement to Rwork/Rfree =
15.8%/16.8% (Supplementary Table S1, apo-VapBC1). The
final model contains a single VapB2C2 heterotetramer in the
crystallographic asymmetric unit (ASU) and is complete for
both VapC1 toxins (residues 2–128) and one VapB1 anti-
toxin (2-79), while the other antitoxin molecule only could
be traced up to residue 63 (Figure 1B, dashed line, Figure
1C and Supplementary Figure S1B). The tetramer interacts
closely with another tetramer related by a crystallographic
2-fold axis and analysis of the interaction energy using PISA
(33) strongly suggests that the relevant, biological entity is
a VapB4C4 heterooctamer, as observed previously for other
VapBC complexes (Figure 1D) (12–13,15–16,18). The com-
plex has a compact structure and is organized with the tox-
ins tightly interacting and forming a large, curved -helical
array with the antitoxin DNA binding domains protruding
below. The complex is stabilised by tight toxin–antitoxin,
toxin–toxin and antitoxin–antitoxin interactions.
C. crescentus VapC1 displays a classical PIN domain
RNase fold with the conserved and mostly acidic residues
(Asp6, Glu40, Asp95, Asn113 and Asp116) in close prox-
imity in the active site (Figure 1B, red sticks and C, dashed
boxes). Like other VapC PIN domain proteins, four VapC1
toxins form two symmetrical homodimers held together by
hydrophobic interactions generating a continuous and pos-
itively charged groove across the top surface near the ac-
tive site cavities (Figure 1D, top). VapB1 consists of an N-
terminal DNA-binding domain that dimerizes to form an
AbrB-typemotif (34) and aC-terminal extended region that
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Figure 1. Overall structure of the C. crescentus CB15 VapBC1 complex. (A) Overview of the genomic organization and regulation of type II TA systems
including VapBC. The TA locus consists of a promoter (P), antitoxin (a) and toxin (t) genes that give rise to a single mRNA expressing two separate
proteins, A (light brown) and T (blue) that associate into a stable complex under normal growth conditions. During stress, the antitoxin is degraded by
cellular proteases activating the toxin, which is a functional RNase targeting specific stable RNA species, including tRNA (lower right). Transcription from
the TA locus is auto-regulated by binding of the TA complex to the promotor (P, top left). (B) Overview of the apo VapBC1 heterotetrameric structure
with the location of the active site indicated by red sticks. One VapC1 toxin is shown in blue and the associated VapB1 antitoxin in light brown with the
N-terminal AbrB domain and two interaction areas with the toxin indicated. The other VapC1 and VapB1 molecules of the tetramer are shown in dark
and light grey, respectively, to highlight the TA interaction. The disordered VapB C terminus is shown with a dashed line. (C) Structure-based sequence
alignment and secondary structure of the Caulobacter crescentus (Ccr) VapC1 and VapB1 proteins with the Shigella flexneri VapBC (Sfl, PDB ID 3TND)
and Rickettsia felis VapBC2 (Rfe, PDB ID 3ZVK) structures (12,13). Sequence numbers correspond to the Caulobacter sequence. Conserved active site
residues in VapC are indicated by dashed boxes (1st, 2nd, 3rd, 4th and 5th) and functional regions of VapB are indicated below the sequence (dashed
lines). The region containing the pseudo-palindromic protein sequence in the VapB C-terminus is likewise indicated (shaded box). The sequences have
been aligned using PROMALS3D (42) and are coloured by the level of similarity (blue = dissimilar, green = some similarity, red = identical). (D) Two
orthogonal views of the heterooctameric apo VapBC1 complex formed by crystallographic symmetry. The VapC1 toxins are shown in light/dark blue with
a semi-transparent surface and the VapB1 antitoxins in light brown/lime. The side view shows the protruding AbrB domains while in the top view, the
positively charged grooves are shown with red. The disordered VapB C termini are shown with dashed lines.
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interacts with the toxin active site in the complex (Figure
1B). Toxin–antitoxin interactions are primarily hydropho-
bic and distributed at two sites, which we term the ‘lateral’
and ‘groove’ sites (Figure 1B). At the lateral site, an -helix
from VapB1 packs against several -helices of VapC1 using
a leucine zipper-like motif (Figure 2A). At the groove site,
the extended C-terminal extension of a single VapB1 anti-
toxin molecule locates into the continuous groove running
across an entire toxin dimer where hydrophobic interactions
anchor it to the surface and conservedArg andGlu residues
make specific interactions with residues in both VapC1 ac-
tive sites (Figure 2B, C and Supplementary Figure S1C).
One VapB1molecule thus inhibits twoVapC1 active sites si-
multaneously (the light brown molecule in Figure 1D) and
the interaction can be described as 1:2. Consequently, the
other VapB1 antitoxin is less tightly associated with the
toxin dimer and only interacts at the lateral site (the green
molecule in Figure 1D), explaining why this molecule only
is visible to residue 63 in the electron density (Supplemen-
tary Figure S1B).
VapC1 inhibition is mediated by a pseudo-palindromic motif
in VapB1
Intriguingly, the C-terminus of VapB1 contains two motifs
of equivalent arginine residues (Arg68 and Arg76) flanked
by two acidic residues on opposite sides (Asp69 and Glu75)
that interact in very similar ways in the two active sites of a
VapC1 dimer (Figure 2C). In this motif, which is part of a
region previously described as conserved (12), the arginine
residues are separated by seven residues of extended pro-
tein structure, which matches the distance between the two
active sites (22 A˚). Moreover, the flanking acidic residues
on either side result in an overall pseudo-palindromic mo-
tif that complements the internal, structural 2-fold symme-
try of the VapC1 dimer (. . .R68D69EDLFPE75R76. . . ). The
VapB1 C-terminus has an extended, -strand like confor-
mation inside the VapC active site with side chains on al-
ternate sides of the peptide backbone (Figure 2C). In the
first part of the motif (R68D69), Arg68 thus points into the
VapC1 active site whilst Asp69 points away and apparently
serves to neutralize a number of positively charged sur-
face residues. This structural motif is then repeated in the
other VapC1monomer only in reverse orientation (E75R76),
with Glu75 pointing away and Arg76 pointing into the
VapC active site. To understand if this type of interaction
is unique to C. crescentus VapBC1 or a more widespread
phenomenon, we first compared our structure to those of
R. felis VapBC2 (13), which exhibits a similar 1:2 bind-
ing of the antitoxin to the toxin and S. flexneri VapBC,
which displays 1:1 binding (12) (Supplementary Figure
S2A). With sequence identities of 21.3%/25.0% (S. flexneri
VapB / VapC) and 25.6%/30.5% (R. felis VapB/VapC),
these proteins are homologous to C. crescentus VapBC1
(Figure 1C) and their crystal structures reveal very similar
heterooctameric assemblies. Intriguingly, in both cases, the
VapB C-termini contain similar pseudo-palindromic motifs
based around two arginine residues exactly eight residues
apart (R. felis VapB2, . . .R66KDLPPQKR74. . . ; S. flexneri
VapB, . . .R64EQPGMQER72. . . ). In the R. felis VapBC2
structure, the two arginine residues from a single antitoxin
molecule are located into the active sites of two VapC2 tox-
ins similarly to what we observe in C. crescentus. In the S.
flexneri VapBC structure, however, only the first arginine
motif of both antitoxins is used in a 1:1 interaction, despite
the presence of a perfect three-letter palindromic sequence
(REQ. . .QER). Both VapB C-termini display a -strand
like fold as observed inC. crescentusVapBC1, with the argi-
nine residue pointing into the active site and the follow-
ing charged residue (K/E) pointing away (Supplementary
Figure S2B). Furthermore, the third residue in the pseudo-
palindromic motif appears to have a conserved acidic or
amide functional group (D/E/Q) that points into the active
site alongside the arginine (Supplementary Figure S2B).
Pseudo-palindromic motifs are widespread among VapB an-
titoxins
To investigate if such pseudo-palindromic motifs are widely
present among VapB antitoxins, we generated a large
set of 4127 putative VapB sequences extracted from all
known bacterial and archaeal genomes and searched for C-
terminal sequence patterns containing two arginine residues
separated by 3 to 12 residues. The sequences were then
sorted by the strength of their pseudo-palindromic charac-
ter using a standard BLOSUM substitution matrix to up-
weigh entries with similar functional groups at equivalent
positions with respect to the palindrome centre (Table 1
and Supplementary Table S2) (32). The analysis reveals that
unique palindromic as well as pseudo-palindromic motifs
are surprisingly common and found among VapB antitox-
ins from a wide range of microbial species including Aci-
dobacteria, Cyanobacteria, Proteobacteria, Spirochaetes,
thermophilic bacteria as well as both branches of archaea,
Crenarchaeota and Euryarchaeota. Roughly 45% of all se-
quences contain a motif in their C-terminus that matches
the R. . .R search pattern and half of these (21.9% of all
sequences) contain a more complex pattern involving one
or more glutamate or aspartate residues on either side
of the arginine residues (Table 1). The most prominent
subclass of these consists of the sequences that contain
‘RE. . .ER’ as part of the pattern (7.3%) and this group
contains some remarkable examples of perfect palindromes
of the type ‘REQ. . .QER’ as also observed in S. flexneri
VapBC (12) and even in some cases ‘EREQ. . .QERE’.
The most complex patterns are found in Proteobacteria
(e.g. Pseudomonas, Acetobacter, Haemophilus, Nitrosococ-
cus) while the ‘REQ. . .QER’ pattern occurs more widely
in both Cyanobacteria, Spirochaetes and Actinobacteria.
Taken together, our sequence analysis demonstrates that
subtle (pseudo-) palindromic sequence patterns appear to
be widespread in the C-terminal extensions of VapB an-
titoxins across both bacteria and archaea. This discovery
supports that the antitoxin C terminus plays an important,
functional role in toxin–antitoxin biology and our struc-
tural data suggest this most likely involves modulation of
either toxin inhibition or regulation of operator binding, or
both.
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Figure 2. Details of toxin–antitoxin interactions. (A) The lateral interaction site is dominated by hydrophobic interactions between VapB1 (light brown)
and VapC1 (blue) in a leucine zipper-like motif. (B) At the groove site, the extended C-terminus of VapB1 (light brown) lies in a hydrophobic groove
spanning the surface of the VapC1 dimer (blue). The VapC1 surface is coloured by hydrophobicity (light blue = hydrophobic, dark blue = hydrophilic)
and relevant, interacting residues in VapB1 are labeled. (C) Overview of the 1:2 antitoxin:toxin interaction of the extended C-terminus of VapB1 (top) and
close-up views of interactions at the two active sites of the VapC1 homodimer (bottom). Conserved acidic residues in the VapC1 active sites are shown in
blue sticks and interacting residues in VapB1 with light brown sticks. VapB1 displays two discrete main chain conformations (A and B) at one site, which
is illustrated with light/dark brown backbone colours.
Table 1. Pseudo-palindromic protein sequence motifs in VapB C-termini.
The table shows a hierarchical view of (pseudo-) palindromic motifs and
their subclasses found in the C-termini of 4127 putative VapB sequences
extracted from all known bacterial and archaeal genome sequences. For
each motif, the number of observations in the set is listed in the right col-
umn along with the percentage of the total
Motif or subclass No. of observations (% of all)
R. . .R 909 (22.03%)
RR. . .RR 68 (1.65%)
RE. . .ER 267 (6.47%)
REQ. . .QER 23 (0.56%)
EREQ. . .QERE 9 (0.22%)
ER. . .RE 144 (3.49%)
R.R. . .R.R 117 (2.83%)
R.E. . .E.R 197 (4.77%)
E.R. . .R.E 79 (1.91%)
VapBC1 distorts operator DNA upon binding
The overall structure of heterooctameric C. crescentus
VapBC1 with two exposed DNA-binding domains suggests
the complex is able to bind directly to the TA promoter, like
other type II TA systems (7). Promoter elements in C. cres-
centus vary somewhat from the canonical sequences found
in E. coli, however, both the −35 and −10 regions required
for  factor binding can be located (35,36). The vapBC1
operator region has been mapped by 5′ RACE and found
to be of the RpoD (73) type (37) (Figure 3A). This region
contains a perfectly palindromic sequence (half-site 1) over-
lapping with the −10 element (TATA box), while the puta-
tive half-site 2 is not clearly palindromic. To test if VapBC1
can bind directly to DNA in this region, we generated a 27-
bp DNA duplex covering both the −10 element and tran-
scription start site and analysed the affinity of the intact
VapBC1 complex in vitro using gel filtration chromatog-
raphy and EMSA. In gel filtration, separation of VapBC1
pre-incubated with DNA results in a new, monodisperse
peak with reversed A260/A280 ratio eluting earlier than the
isolated heterooctamer suggesting formation of a protein-
DNA complex (Figure 3B). In EMSA, titration of the pro-
tein complex into a fixed, low amount of fluorescently la-
belled DNA duplex (10 nM), caused formation of a higher
band already in the low-nanomolar range, which was com-
pletely shifted around 500 nM VapBC1 (Figure 3C). At
higher protein concentrations (>1 M) we additionally ob-
served a super-shifted complex suggesting formation of a
higher-order complex. Together, these experiments conclu-
sively demonstrate that C. crescentus VapBC1 forms a tight
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Figure 3. Operator structure and analysis of DNA binding. (A) Sequence
and organization of the Caulobacter crescentus CB15 vapBC1 operator re-
gion. The −35 and −10 elements are shown with red letters with the con-
sensus from analysis of a range of Caulobacter promoters shown above (S
= C or G, W = A or T, N = any nucleotide, lowercase letters indicate par-
tially conserved positions) (36). The location of the transcription start site,
the palindromic half-site 1 overlapping the −10 region as well as the puta-
tive downstream half-site 2 are indicated with arrows. The region included
in the 27-bp DNA duplex used for crystallography and binding studies is
shown on a grey background. (B) Analysis of binding of a 27-bp DNA
duplex covering half-sites 1+2 to VapBC1 using gel filtration chromatog-
raphy. For both the isolated VapBC and VapBC-DNA, the absorption was
monitored at A280 (solid lines) and A260 (dashed lines). The void volume
(Vo) is approximately 8 ml. (C) DNA binding analysed by EMSA. A 27-bp
fluorescein-labelled DNA duplex was present in a constant concentration
of 10 nM while the VapBC complex was titrated from 6.25 nM to 1.6 M.
The gel shows formation of a stable VapBC-DNA complex with an affinity
in the nanomolar range (bandmarked 1) as well as a higher-order complex
at high protein concentrations (band marked 2).
and stable complex with its operator region with an affinity
in the nanomolar range.
To understand the possible involvement of the antitoxin
C-termini in VapBC operator binding, we next crystallised
this C. crescentus VapBC1-DNA complex and determined
its structure to 2.7 A˚ by molecular replacement using the
apo structure as search model. The structure was iteratively
refined to Rwork/Rfree = 17.8%/24.0% (Supplementary Ta-
ble S1, VapBC1-DNA) and contains a complete VapB4C4
heterooctamer bound to the 27-bp DNA duplex in the crys-
tallographic ASUwith an overall architecture similar to the
apo structure (Figure 4A). The model is complete for all
VapC molecules (2-28), the DNA duplex (1-27) and two
VapB antitoxins (residues 2–79) while the two remaining an-
titoxin molecules (similarly to the apo structure) only could
be traced to around residue 63 (light brown molecules in
Figure 4A). The two half-sites of the vapBC operator re-
gion are located ∼10 nucleotides apart (Figure 3A) and
thus match the phase of the DNA duplex allowing the TA
complex to interact with both half-sites in adjacent major
grooves approaching DNA from the same direction (Sup-
plementary Figure S3A). This is markedly different from
the structure of R. felis VapBC2 bound to DNA, which has
the same overall architecture but is much more open and
approaches the DNA duplex from opposing sides (Supple-
mentary Figure S3B) (13). In the only other known struc-
ture of a VapBC-type TA system bound to DNA, N. gonor-
rhoeae FitAB, the heterooctamer is even more open with no
interactions between the two VapC homodimers (Supple-
mentary Figure S3C) (14). This comparison reveals a sur-
prising variety in DNA interaction modes among homol-
ogous TA complexes that structurally and architecturally
appear very similar.
In the VapBC1-DNA structure, we observe an overall B-
DNA like conformation of the operator region, however,
with significantly expanded major groove widths (16.6 A˚
versus 11.6 A˚ in canonical B-DNA) and a diminished mi-
nor grooves depth (5.5 A˚ versus 8.2 A˚ in B-DNA) (Figure
4A). Despite half-site 2 not being perfectly palindromic, the
structures of the two protein-bound half-sites overlay nearly
perfectly suggesting that the DNA conformation is a direct
result ofVapBbinding and not an intrinsic feature of the op-
erator DNA sequence (Supplementary Figure S4A). Direct
contacts between the VapB1 AbrB domains and DNA are
sparse and symmetrically arranged in the twomajor grooves
(Figure 4B). Arg21 is responsible for the most significant
electrostatic interaction and this position contacts the phos-
phate backbone of DNA in all four antitoxin molecules of
the complex (Figure 4C). Sequence-specific base interac-
tions are found in a few places, most significantly Asn13,
which contacts two guanine bases in half-site 1 (G6 and
G15, Figure 4B and D) while the same side chains of the
corresponding residues in half-site 2 have flipped 180◦ to
be able to interact with adenine (A16 and A22) with re-
versed hydrogen bond polarity (Figure 4B and E). Likewise,
Ser11 forms a sequence-specific hydrogen bond toDNAnu-
cleotide A8 in half-site 2, an interaction which is not possi-
ble half-site 1 where this nucleotide is a pyrimidine (T18)
(Figure 4F). Together, these examples illustrate some of the
flexibility that allowsVapB to adapt to an imperfect pseudo-
palindromic DNA sequence using variable hydrogen bond
patterns.
The VapB1 C-terminal extension is a flexible cross-linking
module
In the apo state, the twoAbrB domains of the VapBC1 com-
plex are close together and physically interact (Supplemen-
tary Figure S4B) while upon binding DNA, the complex
expands nearly 15 A˚ to accommodate the domains into ad-
jacent major grooves (Figure 5A). Opening of the complex
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Figure 4. Structure of VapBC1 bound to operator DNA. (A) Two orthogonal views of the VapBC1 heterooctamer (blue/green/light brown) bound to
DNA with the VapC homotetramer in a semi-transparent surface representation, and DNA bases coloured as in B. In the side view (left), the positions
of half-sites 1 and 2 are indicated with the widths of the major grooves and depth of the minor groove shown. The disordered VapB C termini are shown
with dashed lines. (B) Schematic overview of the interactions between VapBC1 and DNA. Dashed lines indicate hydrogen bonds (blue) and electrostatic
interactions (red) to phosphate groups (pink circles) and bases (coloured rounded squares). Residues in VapB1 are shown in colours matching panel A (light
brown/green). Vertical lines indicate the operator pseudo 2-fold axis separating the two half sites (solid) as well as the half site 2-fold axes (dashed), and
the extent of the two half-sites are indicated as well. (C) Interactions of VapB1 Arg21 with DNA. (D) Interactions of VapB1 Asn13 (chain A) with DNA.
(E) Interactions of VapB1 Asn13 (chain H) with DNA, showing that it flips the side chain to reverse the hydrogen bond polarity in the other molecule. (F)
Interactions of VapB1 Ser11 with DNA. Ser11 forms a base-specific hydrogen bond with A8 in half-site 2.
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Figure 5. The VapB1 C-terminal extension is a flexible cross-linking mod-
ule. (A) Superposition of the VapC homotetramers of the apo (orange)
and DNA-bound (blue) crystal structures of VapBC1 showing that the
AbrB domains move 14.8 A˚ apart upon DNA binding. For both struc-
tures, the antitoxin molecules are shown as coloured ribbons while the
toxin molecules and DNA are in grey. (B) Comparison of the posi-
tions of the VapB1 C-terminal extensions in the apo, DNA-bound and
VapB1C:VapC1 structures annotated as syn or trans. In all cases the an-
titoxins are colour-coded corresponding to their cognate toxin dimer (blue
or green) to highlight how they cross over in the DNA-bound and trun-
cated structures (i.e. blue C-termini bind green toxin dimers). The DNA
duplex is shown with orange ribbons, coloured arrows indicate the direc-
tions of the VapB1 C-termini while dashed arrows indicate the total length
of the octamers. (C) Crystal structure of the VapB1C:VapC1, which has
a DNA-bound like conformation, with colouring like in Figure 1D. The
disordered VapB C termini are shown with dashed lines.
is effectively achieved by rotation of one VapC dimer by
∼25◦ with respect to the other and occurs without disturb-
ing interactions between the toxin and the antitoxin AbrB
domain (Supplementary Figure S4C and Supplementary
Movie). In contrast, DNA binding causes a dramatic rear-
rangement of the VapB1 C-terminal extensions located in
the groove sites, which swap places as the complex opens
up (Figure 5B). More precisely, the ‘outermost’ VapB1 ter-
mini reach around and interact with both molecules of a
toxin dimer in the apo state (Figure 5B, apo), whereas the
‘innermost’ VapB1 termini interact in theDNA-bound state
(Figure 5B, DNA-bound). An important structural conse-
quence of this is that theVapC1 toxin dimers are inhibited in
syn by their cognate VapB1 antitoxins in the apo state (i.e.
those antitoxins that belong to the same tetramer), while
they interact in trans with antitoxins belonging to the other
heterotetramer in the DNA-bound state. This rearrange-
ment is apparently a direct result of the overall stretching
of the TA complex by nearly 5 A˚ in length as required for
DNA binding and made possible by relatively small differ-
ences in the number of interactions between the two states.
Once the VapB1 C-termini have swapped positions, interac-
tions between the pseudo-palindromic sequence in the anti-
toxin and the VapC1 active sites are nearly identical to the
apo state, but occur in the reverse direction. Together, these
observations suggest that theVapB1C-terminal extension is
a flexible module that is able to cross-link the VapC1 dimers
in at least two different ways in the heterooctamer depend-
ing on whether DNA is bound or not and is therefore likely
important for regulation of DNA binding.
C-terminal truncation of VapB1 does not induce a 1:1
toxin:antitoxin interaction
Since the observed 2:1 interaction of toxin to antitoxin only
utilizes half of the toxin-binding potential of the available
VapB1 C-termini, we finally asked what would happen if
the C-terminus was truncated to only contain a single VapC
binding site, which would correspond to a 1:1 molar ra-
tio between binding sites on the antitoxins and VapC ac-
tive sites in the complex. To answer this question, we in-
troduced a stop codon at position 73 in the gene coding
for VapB1 and purified the resulting truncated complex to
homogeneity. In vivo, the truncated antitoxin displayed re-
duced activity (Supplementary Figure S1A), nevertheless,
the oligomeric state of the VapBC complex remained stable
as judged from gel filtration chromatography (Supplemen-
tary Figure S5). We next proceeded to crystallize the com-
plex between this truncated version of VapB1 and VapC1
and determined the structure to 1.9 A˚ bymolecular replace-
ment using the apo structure as search model, built and it-
eratively refined the model to Rwork/Rfree = 19.6%/23.9%
(Supplementary Table S1, VapB1C:VapC1). The struc-
ture contains 12 protein chains per ASU, organized in a
VapB4C4 heterooctamer (Figure 5C) and a VapB2C2 het-
erotetramer. The heterotetramer is related by 2-fold crys-
tallographic symmetry to a neighbouring complex gener-
ating a second, complete heterooctamer, which is identical
to the first within experimental error (Supplementary Fig-
ure S4D, r.m.s.d C atoms = 0.73 A˚). All six toxin chains
(residues 2–128) and three of the antitoxin chains (2-7) are
essentially complete, while the remaining three antitoxin
chains only could be traced to the end of the lateral bind-
ing site around residue 65 (light brown molecule in Fig-
ure 5C) as seen before. The overall conformation of the
complex is somewhere in-between the apo andDNA-bound
forms but closest to the DNA-bound form with the VapB1
AbrB domains well separated and with an overall stretched
VapC1 complex (Figure 5B, VapB1C:VapC1). Consistent
with this, the VapB1 C-terminal extensions interact with
the VapC1 active sites in trans like observed in the DNA-
bound form, which suggests that the free TA complex exists
in an equilibrium between the tight (apo) and more open
(DNA-bound/truncated) conformations. Surprisingly, we
find a 1:2-like interaction to be preserved in the truncated
structure, i.e. only one VapB1 C-terminal extension inter-
acts with each toxin dimer while the other C-terminal exten-
sion remains disordered. Since the C-terminus is truncated,
this means that only half the VapC1 active sites are inhib-
ited, while the other are not interacting with an antitoxin at
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all. Overall, the electron density for the antitoxin molecules
is significantly poorer than for the full-length structure, par-
ticularly near the C-termini. Most significantly, the helix at
one of the lateral sites appears to have become partly un-
structured (left, light brown molecule in Figure 5C), sug-
gesting that VapB in the cleaved state is less tightly bound
than in the intact form.
DISCUSSION
In this paper, we show that C. crescentus VapBC1 forms
a flexible macromolecular complex able to adapt to DNA
binding via conformational changes, including a dramatic
reorganization of stable toxin–antitoxin interactions. Flex-
ibility in toxin and antitoxin interactions is not uncommon
and switching of antitoxin C-termini have also been ob-
served in other structurally unrelated TA systems such as
ccdAB and MazEF suggesting it may be a general prin-
ciple in TA biology (10,38–39). For the antitoxin VapB1,
we identify a sequence pattern in the C-terminus that is di-
rectly involved in toxin inactivation and show that this is
a widespread feature of both bacterial and archaeal VapB
antitoxins. We also show that the pseudo-palindromic na-
ture of this sequence is the structural basis for inhibition
of the VapC toxin in a 1:2 ratio, with each half of the mo-
tif locating into individual VapC1 active sites (13,15). One
might therefore speculate that the presence of such pseudo-
palindromic sequences can be used to predict whether VapB
antitoxins interact in a 1:1 or 1:2 ratio with their cognate
toxins. However, analysis of available TA structures reveals
that this does not appear to be the case: S. flexneri VapB
binds in a 1:1 ratio to its cognate VapC toxin despite con-
taining a perfect REQ. . .QER palindromic sequence, thus
leaving the second part of the palindromic motif of both
antitoxin molecules disordered in the structure (12). Nev-
ertheless, we can conclude the sequence signature observed
in S. flexneri VapBC is perfectly compatible with 1:2 bind-
ing and suggests that another conformation of the complex
might exist thatmakes use of the full C-terminus, e.g. during
operator DNA binding. Likewise, it was demonstrated that
M. tuberculosis VapBC-15 can display both 1:1 and 1:2 in-
teractions, which adds further support to the notion that the
interaction is highly dynamic and depends on the functional
state of the TA complex (15). The structure of C-terminally
truncated VapB1 bound to VapC1 sheds further light on
this surprisingly complex structural flexibility, showing that
one of the two VapB1 antitoxin molecules does not bind to
VapC despite the presence of a nearby unoccupied groove
site. This strongly suggests that it is the overall conforma-
tion of the TA complex, not the availability of binding sites
that dictates the location of the C-termini. The observation
that the TA complex stretches upon binding DNA in order
to locate the AbrB motifs into adjacent major grooves fur-
ther highlights this.
For those VapBC pairs for which VapB contains a
pseudo-palindromic motif, we can conclude that regard-
less of whether 1:1 or 1:2 binding is observed, only 50%
of the VapC binding capacity of VapB is used at any time.
Either both antitoxin molecules interact with one VapC
active site each (proximal/distal 1:1 interaction) and the
other half of the palindromic motif is left unused, or one
molecule uses both its interaction sites and the other none
of them (1:2). One possible rationale for this apparent ex-
cess of VapC binding sites is that they are important for co-
operativity in TA complex formation or toxin activation, or
both. For example, the unused binding sites would allow ad-
ditional toxin molecules to bind during activation and thus
promote further destabilization of TA complex. For some
TA systems, such as Phd/Doc and RelBE, a phenomenon
known as ‘conditional cooperativity’ in DNA binding has
been described, in which additional toxin molecules join the
TA complex at high concentration, causing destabilization
of DNA binding and consequently de-repression (9,10). A
similar mechanism, by which excess VapC is able to break a
VapBC DNA complex has been demonstrated for S. enter-
ica LT2 VapBC, however, the structural basis for this mech-
anism, remains to be elucidated (40).
This paper presents for the first time structures of the
same TA complex both on and off DNA and the struc-
tures surprisingly reveal that the C-terminal extensions of
the antitoxin molecules switch place upon DNA binding.
The result of this is that a C-terminal extension of one T2A2
heterotetramer stretches across and binds the toxin dimer
in the other heterotetramer of the complex in the DNA
bound state in trans, thus effectively cross-linking the com-
plex while bound to DNA (Figure 5B, DNA-bound, blue
ribbons). Conversely, in the apo state, the C-terminal ex-
tensions of VapB1 interact with their cognate VapC1 dimer
in a syn interaction (Figure 5B, apo, green ribbons). In this
state, the two heterotetramers are essentially free to dissoci-
ate, while they are cross-linked and interlocked in theDNA-
bound state. The structure of C-terminally truncatedVapB1
bound to VapC1 suggests that a destabilization of one of
the VapC1-interacting helices of the antitoxin molecules oc-
curs (Figure 5C, left, light-brown molecule). In vivo, the an-
titoxins are degraded by cellular proteases during toxin ac-
tivation. It is therefore possible that the truncated structure
represents a distinct step on the path to activation where
the antitoxin is starting to dissociate. It is also possible that
the observed flexibility of full-length VapB plays a role in
toxin activation by allowing access of a stress-induced pro-
tease to the antitoxin C-terminus. In fact, it was shown for
the ccdAB TA system that the protease cleaves through-
out the C-terminus of the antitoxin, suggesting that the C-
terminal region of VapB could be a target for the protease
(41). From a structural perspective it also makes sense that
the C-terminus, being extended and partly flexible, would
be the prime target during activation.
Taken together, our observations can be summarised in a
model for transcriptional repression and toxin activation in
the VapBC TA class (Figure 6). Under normal growth con-
ditions (when the toxin is inhibited), the VapB C-terminal
extensions inhibit toxins in syn in a 1:2 ratio, which would
allow the heterotetramers to dissociate and re-associate.
DNA binding, on the other hand, stretches the complex
and forces the C-termini to swap places, thus interlock-
ing the TA complex while bound to the operator region
and possibly at the same time preventing attack of the pro-
tease. During the structural rearrangements, the C-termini
would be vulnerable to proteolytic cleavage and such an
event would destabilise the TA complex as visualised in the
VapB1C:VapC1 complex structure, eventually leading to
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Figure 6. Model for DNA binding and activation of the VapBC-type tox-
ins. Non-crosslinked VapBC tetramers can associate into heterooctamers
that are able to bindDNA,which causes the extendedC-termini of VapB to
switch position and interlock the complex while bound to operator DNA.
The flexibility of the C-termini also allows access of a stress-induced pro-
tease to the extended protein segments and this cleavage further destabi-
lizes the complex, eventually leading to toxin activation.
release of VapC toxin dimers. With these important new
concepts in hand, functional studies should now be under-
taken in vivo and in vitro produce a complete picture of
the molecular mechanisms underlying DNAbinding, cross-
linking and toxin activation for VapBC-type TA systems. In
particular, it would be worthwhile to demonstrate to which
extent and by which mechanism conditional cooperativity
is involved in regulating VapBC transcription.
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